ADC Therapeutics (ADCT) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic evolution and portfolio focus

• Streamlined portfolio to focus on areas with strong differentiation, especially in hematology and solid tumors.

• Broadened research platform beyond PBD payloads to include multiple payloads, linkers, and antibody constructs.

• Reduced cost base by 25%-30% over two years.

• Prioritized lifecycle management for Zynlonta and advanced solid tumor strategy.

Zynlonta: current status and market opportunity

• Zynlonta is approved as monotherapy for third-line DLBCL, offering rapid, deep, and durable responses with manageable safety.

• Achieves a 25% CR rate as a single agent in late lines, with durable responses and no median duration reached after two years.

• No REMS or inpatient requirements, making it accessible and easy to administer.

• Current sales are around $70 million, with a peak opportunity of $80-$100 million in third-line DLBCL.

Expansion into earlier lines and combination strategies

• Targeting second-line DLBCL with bispecific and ADC/antibody-based combinations, expecting these segments to grow.

• Ongoing phase I trial (LOTIS-7) combines Zynlonta with Glofitamab, with no high-grade CRS or ICANS observed.

• Full enrollment of 40 patients expected by year-end, with initial data later this year and full readout in H1 next year.

• Phase III LOTIS-5 study compares Zynlonta plus Rituximab to R-GEMOX, with enrollment to complete this year and readout by end of next year.